Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

Stefanie Schüpke, Franz-Josef Neumann, Maurizio Menichelli, Katharina Mayer, Isabell Bernlochner, Jochen Wöhrle, Gert Richardt, Christoph Liebetrau, Bernhard Witzenbichler, David Antoniucci, Ibrahim Akin, Lorenz Bott-Flügel, Marcus Fischer, Ulf Landmesser, Hugo A Katus, Dirk Sibbing, Melchior Seyfarth, Marion Janisch, Duino Boncompagni, Raphaela Hilz, Wolfgang Rottbauer, Rainer Okrojek, Helge Möllmann, Willibald Hochholzer, Angela Migliorini, Salvatore Cassese, Pasquale Mollo, Erion Xhepa, Sebastian Kufner, Axel Strehle, Stefan Leggewie, Abdelhakim Allali, Gjin Ndrepepa, Helmut Schühlen, Dominick J Angiolillo, Christian W Hamm, Alexander Hapfelmeier, Ralph Tölg, Dietmar Trenk, Heribert Schunkert, Karl-Ludwig Laugwitz, Adnan Kastrati
New England Journal of Medicine 2019 October 17, 381 (16): 1524-1534

BACKGROUND: The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain.

METHODS: In this multicenter, randomized, open-label trial, we randomly assigned patients who presented with acute coronary syndromes and for whom invasive evaluation was planned to receive either ticagrelor or prasugrel. The primary end point was the composite of death, myocardial infarction, or stroke at 1 year. A major secondary end point (the safety end point) was bleeding.

RESULTS: A total of 4018 patients underwent randomization. A primary end-point event occurred in 184 of 2012 patients (9.3%) in the ticagrelor group and in 137 of 2006 patients (6.9%) in the prasugrel group (hazard ratio, 1.36; 95% confidence interval [CI], 1.09 to 1.70; P = 0.006). The respective incidences of the individual components of the primary end point in the ticagrelor group and the prasugrel group were as follows: death, 4.5% and 3.7%; myocardial infarction, 4.8% and 3.0%; and stroke, 1.1% and 1.0%. Definite or probable stent thrombosis occurred in 1.3% of patients assigned to ticagrelor and 1.0% of patients assigned to prasugrel, and definite stent thrombosis occurred in 1.1% and 0.6%, respectively. Major bleeding (as defined by the Bleeding Academic Research Consortium scale) was observed in 5.4% of patients in the ticagrelor group and in 4.8% of patients in the prasugrel group (hazard ratio, 1.12; 95% CI, 0.83 to 1.51; P = 0.46).

CONCLUSIONS: Among patients who presented with acute coronary syndromes with or without ST-segment elevation, the incidence of death, myocardial infarction, or stroke was significantly lower among those who received prasugrel than among those who received ticagrelor, and the incidence of major bleeding was not significantly different between the two groups. (Funded by the German Center for Cardiovascular Research and Deutsches Herzzentrum München; ISAR-REACT 5 number, NCT01944800.).

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.


Sort by: Most RecentHighest Rated

Vic Froelicher

233 Were excluded from analysis in one arm and 3 in the other; also different protocols were used in each arm. The results may not have clinical significance


Trending Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"